Related Experiment Video
Updated: Oct 12, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.7K
Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?
Patricia Martin-Romano1, Julien Adam2, Jean-Yves Scoazec2
1Early Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
Frontiers in Immunology
|November 22, 2021
Summary
Radiotherapy may alter the tumor immune microenvironment, affecting responses to immunotherapy. This case study explores how prior radiation impacts anti-PD1 treatment effectiveness in anal cancer.
Area of Science:
- Oncology
- Immunology
- Radiation Oncology
Background:
- Immunotherapy, particularly immune checkpoint inhibitors like anti-PD1 agents, has revolutionized cancer treatment.
- The influence of prior radiotherapy (RT) on the efficacy of subsequent immunotherapy remains largely unexplored.
- Understanding this interaction is crucial for optimizing cancer treatment strategies.
Observation:
- A 58-year-old female with squamous anal cell carcinoma, previously treated with RT, exhibited a variable response to anti-PD1 therapy.
- Tissue analysis from RT-treated and RT-untreated lesions revealed distinct immune microenvironments.
- Differences in immune cell infiltration and cytokine profiles were noted between the two lesion types.
Findings:
- Prior radiotherapy significantly modulated the immune contexture within the tumor microenvironment.
- Specific alterations in immune cell populations and their spatial distribution were observed in RT-affected tissues.
- These changes in the immune landscape may explain the dissociated response to immunotherapy.
Implications:
- Radiotherapy could precondition the tumor microenvironment, influencing immunotherapy outcomes.
- Further research is warranted to elucidate the mechanisms by which RT affects anti-PD1 therapy response.
- Tailoring treatment sequencing based on prior RT exposure may improve patient responses to immunotherapy.
